IsoPet Cancer Therapy

IsoPet Cancer Therapy IsoPet®️Precision Radionuclide Therapy™️ is a safer and more effective targeted cancer treatment for solid tumors in all animals. Visit www.IsoPet.com.

IsoPet®️is a internationally registered trademark of Vivos Inc. Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (IsoPet®) and in humans (RadioGel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers. RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected. RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members. The IsoPet® Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019. In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of IsoPet® to University animal hospitals and private veterinary clinics. IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

Today is a day to recognize our vets and a perfect time to give a little shout-out to all those forward-thinking vets ou...
12/09/2025

Today is a day to recognize our vets and a perfect time to give a little shout-out to all those forward-thinking vets out there that have come on board with us in 2025 to offer their patients a safer cancer treatment option with IsoPet®

Soft tissue sarcoma is something our vets see often, and it can be unsettling for any pet parent. We put together an eas...
12/04/2025

Soft tissue sarcoma is something our vets see often, and it can be unsettling for any pet parent. We put together an easy to follow blog that explains the signs and symptoms so you can stay informed without feeling overwhelmed.

Soft tissue sarcoma is a type of cancer that affects the connective tissues in pets, including muscles, tendons, and fat. This diagnosis can be overwhelming for pet owners, but understanding the condition, its symptoms, treatment options, and potential outcomes can help you make informed decisions a...

Our cutting edge cancer treatment, Precision Radionuclide Therapy™ is showing incredible results for this horse Tilly on...
11/13/2025

Our cutting edge cancer treatment, Precision Radionuclide Therapy™ is showing incredible results for this horse Tilly on an inoperable sarcoma! Warning: graphic but heartwarming images below! IsoPet® is changing the way cancer is treated!

We love when we receive updates from our pet patients one year later - Jazper truly captures the life changing impact of...
11/03/2025

We love when we receive updates from our pet patients one year later - Jazper truly captures the life changing impact of our safer and more effective cancer treatment. IsoPet® Precision Radionuclide Therapy™ WORKS to kill cancer from the inside out!

Today marks the 100th press release since Dr. Michael Korenko took the helm as CEO of Vivos Inc. Today’s announcement de...
10/29/2025

Today marks the 100th press release since Dr. Michael Korenko took the helm as CEO of Vivos Inc. Today’s announcement deepens our collaboration with Exubrion Therapeutics — a strategic move to accelerate innovation in radioisotope therapies for multiple indications in companion animals. To read the full press release visit VivosInc.com

10/28/2025

Big news! Our cutting-edge precision radionuclide treatment (PRnT) is making headlines — thanks to our feature on CBS News Philadelphia. Read how we’re delivering targeted radiation directly into tumors for pets and redefining veterinary oncology!

Big news! Our cutting-edge precision radionuclide treatment (PRnT) is making headlines — thanks to our feature on CBS Ne...
10/28/2025

Big news! Our cutting-edge precision radionuclide treatment (PRnT) is making headlines — thanks to our feature on CBS News Philadelphia. Read how we’re delivering targeted radiation directly into tumors for pets and redefining veterinary oncology:

https://www.cbsnews.com/philadelphia/news/radiation-therapy-cancer-dogs-new-jersey/

Anu, a bulldog, has the most common form of canine skin cancer, and she underwent the new radiation therapy that uses radio gel.

Here’s a look at the types of cancers being treated by IsoPet. Early detection is the key to successful cancer treatment...
09/15/2025

Here’s a look at the types of cancers being treated by IsoPet. Early detection is the key to successful cancer treatment. Have lumps and bumps on your pets looked at by your local veterinarian and visit our website IsoPet.com

IsoPet Precision Radionuclide Therapy is a new way of treating cancer and can be a safer, more effective treatment for y...
09/02/2025

IsoPet Precision Radionuclide Therapy is a new way of treating cancer and can be a safer, more effective treatment for your pet.

Visit www.IsoPet.com to find the treatment center closest to you.

IsoPet is being performed in 15 veterinarian hospitals and university partners in the USA and we are looking to expand so pets do not have to travel as far.

If you are a veterinarian interested in becoming certified to inject our treatment please send us a message for more information.

We love conference season where we can meet veterinarians from across the country and promote IsoPet as another option f...
08/27/2025

We love conference season where we can meet veterinarians from across the country and promote IsoPet as another option for treating cancer in pets! Visit our website www.IsoPet.com for more information on our cancer treatment.

Welcome Capital Veterinary Specialists in Tallahassee, Florida for becoming our first small animal clinic using IsoPet t...
08/21/2025

Welcome Capital Veterinary Specialists in Tallahassee, Florida for becoming our first small animal clinic using IsoPet to treat pet cancer.

They join the University of Florida’s Large Animal Hospital as certified IsoPet treatment centers.

Please visit their website to book a consultation to see if your pet is a candidate for our safer cancer treatment.

IsoPet is treating cancer as an out patient procedure and in most cases in just one treatment! Visit us at www.IsoPet.com for more information.

Address

Suite N288 1030 N. Center Parkway
Kennewick, WA
99336

Website

Alerts

Be the first to know and let us send you an email when IsoPet Cancer Therapy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to IsoPet Cancer Therapy:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Vivos Inc. (OTCQB: RDGL) Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.